24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
HYCALIEVA 2.5MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | HYCALIEVA 2.5MG |
|---|---|
| Composition | Topotecan Injection IP 2.5mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
Topotecan Injection IP 2.5mg (Topotecan Injection IP 2.5mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
HYCALIEVA 2.5 MG (Topotecan Injection IP 2.5 mg) is a prescription anticancer medicine used for the treatment of specific types of cancer, including ovarian cancer, small cell lung cancer (SCLC), and cervical cancer. It contains Topotecan 2.5 mg, a potent chemotherapy agent belonging to the class of medicines known as topoisomerase I inhibitors. The medicine works by interfering with the DNA replication process in cancer cells, helping to slow tumor growth and prevent the spread of cancer.
Cancer develops when abnormal cells multiply uncontrollably. These rapidly dividing cells require continuous DNA replication to survive and spread. Topotecan blocks an enzyme called topoisomerase I, which plays a critical role in DNA repair and replication. By inhibiting this enzyme, HYCALIEVA 2.5 MG causes damage to cancer cell DNA, leading to cell death and reduced tumor progression.
Topotecan is widely used in oncology treatment programs and may be prescribed when certain cancers recur, progress after previous treatment, or require additional chemotherapy support. It is commonly administered in hospitals, cancer centers, and specialized oncology facilities under the supervision of trained healthcare professionals.
HYCALIEVA 2.5 MG is commonly prescribed for:
• Ovarian Cancer
• Recurrent Ovarian Cancer
• Small Cell Lung Cancer (SCLC)
• Relapsed Small Cell Lung Cancer
• Advanced Cervical Cancer
• Metastatic Cancer Management
• Combination Chemotherapy Protocols
• Oncology Treatment Programs
The medicine may be used alone or in combination with other anticancer agents depending on the type of cancer, stage of disease, and individual treatment goals.
Manufactured under strict pharmaceutical quality standards, HYCALIEVA 2.5 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals experienced in chemotherapy and cancer care.
Patients receiving Topotecan therapy typically require routine blood tests, liver and kidney function monitoring, and regular medical assessments to evaluate treatment response and manage potential side effects.
Due to its established role in cancer treatment, HYCALIEVA 2.5 MG remains an important component of modern oncology care and chemotherapy protocols.
HYCALIEVA 2.5 MG (Topotecan Injection IP 2.5 mg) is primarily used for the treatment and management of specific cancers.
The medicine is used in patients with ovarian cancer, particularly when the disease has returned after initial treatment.
Doctors may prescribe Topotecan for relapsed or recurrent small cell lung cancer.
HYCALIEVA may be included in treatment plans for advanced or recurrent cervical cancer.
The medicine helps manage cancers that have spread to other parts of the body.
Topotecan is often used alongside other anticancer medicines to improve treatment outcomes.
The medicine supports comprehensive cancer treatment strategies and long-term disease control.
Topotecan belongs to a class of medicines known as Topoisomerase I Inhibitors.
HYCALIEVA works by:
• Blocking the topoisomerase I enzyme
• Preventing proper DNA replication
• Damaging cancer cell DNA
• Inhibiting cancer cell division
• Slowing tumor growth
• Supporting effective chemotherapy treatment
This mechanism helps destroy rapidly dividing cancer cells and reduces disease progression.
Like all chemotherapy medicines, HYCALIEVA 2.5 MG may cause side effects in some patients. The occurrence and severity of side effects vary depending on individual response and treatment duration.
Weakness and low energy levels are commonly reported.
Patients may experience mild to moderate nausea during treatment.
Episodes of vomiting may occur in some individuals.
Digestive disturbances and loose stools may develop.
Reduced appetite is a frequently reported side effect.
Temporary hair thinning or hair loss may occur.
Mild fever may develop during therapy.
Some patients may experience stomach discomfort or abdominal pain.
Topotecan may reduce:
• White blood cell counts
• Red blood cell counts
• Platelet counts
This may increase the risk of infection, anemia, and bleeding.
Seek immediate medical attention if you experience:
• High fever
• Signs of severe infection
• Unusual bleeding or bruising
• Severe diarrhea
• Difficulty breathing
• Severe allergic reactions
• Persistent vomiting
• Severe weakness
• Chest pain
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of HYCALIEVA 2.5 MG (Topotecan Injection IP 2.5 mg) should always be determined by a qualified oncologist or healthcare professional.
Dosage depends on the cancer diagnosis and treatment protocol.
Chemotherapy dosing is commonly calculated according to body size.
Patients with kidney impairment may require dosage adjustments.
Treatment decisions may depend on blood test results.
Doctors may modify treatment based on effectiveness and side effect management.
• The injection should only be administered by trained healthcare professionals.
• Follow the prescribed chemotherapy schedule carefully.
• Attend all scheduled treatment sessions.
• Regular blood monitoring is essential during therapy.
• Do not alter treatment schedules without medical guidance.
• Inform your doctor about any unusual symptoms experienced during treatment.
Before receiving treatment, patients should inform their doctor if they have:
• Kidney disease
• Liver disease
• Blood disorders
• Active infections
• Previous chemotherapy-related complications
• Allergies to medications
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
• Store according to manufacturer recommendations.
• Protect from direct sunlight and excessive heat.
• Keep out of reach of children.
• Follow hospital and pharmacy storage guidelines.
• Trusted Topotecan formulation
• Effective chemotherapy treatment option
• Supports ovarian, cervical, and lung cancer management
• Used in internationally recognized oncology protocols
• Manufactured under strict pharmaceutical quality standards
• Reliable therapeutic performance
• Suitable for advanced cancer treatment programs
It is used for the treatment of ovarian cancer, small cell lung cancer, cervical cancer, and certain other advanced cancers.
Topotecan is a chemotherapy medicine that blocks topoisomerase I, helping prevent cancer cell growth and replication.
Yes, it is a chemotherapy medicine belonging to the topoisomerase I inhibitor class.
Yes, it is often used as part of combination chemotherapy treatment plans.
Yes, Topotecan may reduce white blood cells, red blood cells, and platelets, requiring regular monitoring.
Yes, doctors typically recommend blood tests, kidney function assessments, and routine medical evaluations throughout therapy.
No, chemotherapy treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.